Nurix therapeutic price target was reduced to $ 36 at HC Wainwright $ 34

HC Wainwright has dropped the firm Price target In Nurix Therapistics (Garport) Up to $ 36 and keeps a purchase rating in stocks. Last week, Nurix, per share (62c) reported a slightly narrow loss of the company (52C). The company continues to progress in larger operating costs.

Was first published Tort – Real-time mode, the last source for financial news moving in the market. Try it now >>

See Todranks to the best working shares today >>

Read more Read at NRIX:

Refusal and DisclosureReport an issue